Get Details
Get Details

Scientific Presentations & Publications

Drug development backed by sound research.

The publications and presentations highlighted below represent a sample of the team’s innovative research published by the Coherus team and our collaborators.

11/09/24

CHS-114, an anti-CCR8 cytolytic monoclonal antibody that preferentially depletes intratumoral Tregs and induces antitumor immune responses

Ravindranathan, S., et al. 2024 SITC Annual Meeting

11/08/24

Casdozokitug, a first-in-class, anti-IL27 antagonistic antibody treatment promotes NK and T cell driven antitumor response in a Phase I study in patients with advanced solid tumors

Wang, X., et al. 2024 SITC Annual Meeting

10/21/24

Casdozokitug, a first-in-class, anti-IL27 antagonistic antibody treatment promotes NK and T cell driven activation and inflammatory response in a Phase I study of cancer patients with advanced solid tumors

Rajasekaran, N., et al. Cytokines 2024

09/10/24

CHS-114, an Anti-CCR8 Antibody That Selectively Depletes Intratumoral Tregs and Induces Antitumor Immune Responses

Wang, X. et al., CICON24, CRI-ENCI-AACR INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE

09/08/24

Casdozokitug, a First-in-Class, Anti-IL-27 Antagonistic Antibody, Treatment Promotes NK and T cell Activation and Inflammatory Response in Phase I Study of Cancer Patients with Advanced Solid Tumors

Ravindranathan, S., et al. CICON24, CRI-ENCI-AACR INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE

06/01/24

Preliminary results of a phase 1, first-in-human, dose escalation study of the anti-CCR8 cytolytic antibody, CHS-114 (formerly SRF114) in patients with advanced solid tumors

Patnaik, A., et al. 2024 ASCO Annual Meeting

04/08/24

Characterization of CHS-1000, an Fc-modified anti-ILT4 monoclonal antibody for reprogramming suppressive myeloid cells in solid tumors

Rajasekaran, N., et al. 2024 AACR Annual Meeting

02/29/24

Toripalimab, a Next-Generation Designed Anti-PD-1 Antibody for Treatment of Nasopharyngeal Carcinoma

Rajasekaran, et al. 2024 Multidisciplinary Head and Neck Cancer Symposium

02/29/24

CHS-114: a Cytolytic Anti-CCR8 Antibody that Depletes Tumor-Infiltrating Regulatory T Cells as a Treatment for Head and Neck Squamous Cell Carcinoma

Rajasekaran, et al. 2024 Multidisciplinary Head and Neck Cancer Symposium

02/24/24

Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells

Rajasekaran, N., Wang, X., Ravindranathan, S. et al. Cancer Immunol Immunother 73, 60 (2024)

12345

We have multiple novel immuno-oncology programs currently in our development pipeline.

See our Pipeline